Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	histone H4K20 demethylase activity	PHF2 PHF8	2.00e-05	4	37	2	GO:0035575
GeneOntologyMolecularFunction	histone H4 demethylase activity	PHF2 PHF8	3.33e-05	5	37	2	GO:0141058
GeneOntologyMolecularFunction	histone H3K9 demethylase activity	PHF2 PHF8	3.00e-04	14	37	2	GO:0032454
GeneOntologyMolecularFunction	histone H3 demethylase activity	PHF2 PHF8	1.23e-03	28	37	2	GO:0141052
GeneOntologyMolecularFunction	histone binding	PHF2 PHF8 AASS SUPT6H	1.42e-03	265	37	4	GO:0042393
GeneOntologyMolecularFunction	histone demethylase activity	PHF2 PHF8	1.50e-03	31	37	2	GO:0032452
GeneOntologyMolecularFunction	protein demethylase activity	PHF2 PHF8	1.60e-03	32	37	2	GO:0140457
GeneOntologyBiologicalProcess	negative regulation of rDNA heterochromatin formation	PHF2 PHF8	3.13e-06	2	37	2	GO:0061188
GeneOntologyBiologicalProcess	regulation of rDNA heterochromatin formation	PHF2 PHF8	9.38e-06	3	37	2	GO:0061187
GeneOntologyBiologicalProcess	dentate gyrus development	PTEN VPS13B LARGE1	2.31e-05	31	37	3	GO:0021542
GeneOntologyBiologicalProcess	negative regulation of osteoclast development	TJP2 CLDN18	4.68e-05	6	37	2	GO:2001205
GeneOntologyBiologicalProcess	negative regulation of heterochromatin formation	PHF2 PHF8	4.68e-05	6	37	2	GO:0031452
GeneOntologyBiologicalProcess	negative regulation of chromatin organization	PHF2 PHF8	6.54e-05	7	37	2	GO:1905268
GeneOntologyBiologicalProcess	localization within membrane	EFR3B CACNB2 SORBS1 FYN VPS13B VPS50 FRMPD1 LARGE1	6.90e-05	798	37	8	GO:0051668
GeneOntologyBiologicalProcess	limbic system development	PTEN RAX VPS13B LARGE1	1.16e-04	141	37	4	GO:0021761
GeneOntologyBiologicalProcess	rDNA heterochromatin formation	PHF2 PHF8	1.40e-04	10	37	2	GO:0000183
GeneOntologyBiologicalProcess	protein demethylation	PHF2 PHF8	1.40e-04	10	37	2	GO:0006482
GeneOntologyBiologicalProcess	protein dealkylation	PHF2 PHF8	1.40e-04	10	37	2	GO:0008214
GeneOntologyBiologicalProcess	nucleolar chromatin organization	PHF2 PHF8	1.70e-04	11	37	2	GO:1990700
GeneOntologyBiologicalProcess	forebrain development	PTEN FYN RAX VPS13B CDON LARGE1	2.14e-04	489	37	6	GO:0030900
GeneOntologyBiologicalProcess	regulation of osteoclast development	TJP2 CLDN18	2.41e-04	13	37	2	GO:2001204
GeneOntologyBiologicalProcess	neuromuscular junction development	CACNB2 SORBS1 LARGE1	2.46e-04	68	37	3	GO:0007528
GeneOntologyBiologicalProcess	cell junction organization	APC TJP2 CLDN18 CACNB2 SORBS1 PTEN FYN LARGE1	2.73e-04	974	37	8	GO:0034330
GeneOntologyCellularComponent	apical junction complex	APC TJP2 CLDN18 SORBS1	1.71e-04	158	37	4	GO:0043296
GeneOntologyCellularComponent	adherens junction	APC TMOD3 TJP2 SORBS1	5.22e-04	212	37	4	GO:0005912
GeneOntologyCellularComponent	cytoplasmic side of membrane	TGM3 PTEN RASA3 EEF1A2	7.09e-04	230	37	4	GO:0098562
Domain	SH3	TJP2 CACNB2 SORBS1 FYN	8.52e-04	216	37	4	SM00326
Domain	SH3	TJP2 CACNB2 SORBS1 FYN	8.52e-04	216	37	4	PS50002
Domain	SH3_domain	TJP2 CACNB2 SORBS1 FYN	9.12e-04	220	37	4	IPR001452
Domain	JmjC	PHF2 PHF8	1.03e-03	24	37	2	PF02373
Domain	Guanylate_kin	TJP2 CACNB2	1.20e-03	26	37	2	PF00625
Domain	GK/Ca_channel_bsu	TJP2 CACNB2	1.20e-03	26	37	2	IPR008145
Domain	Guanylate_kin-like_dom	TJP2 CACNB2	1.20e-03	26	37	2	IPR008144
Domain	GuKc	TJP2 CACNB2	1.20e-03	26	37	2	SM00072
Domain	JMJC	PHF2 PHF8	1.82e-03	32	37	2	PS51184
Domain	JmjC_dom	PHF2 PHF8	1.82e-03	32	37	2	IPR003347
Domain	JmjC	PHF2 PHF8	1.94e-03	33	37	2	SM00558
Domain	SH3_1	CACNB2 SORBS1 FYN	4.15e-03	164	37	3	PF00018
Pubmed	Systematic proteomics of endogenous human cohesin reveals an interaction with diverse splicing factors and RNA-binding proteins required for mitotic progression.	PHF2 TMOD3 TGM3 RNF2 SUPT6H MATR3	4.11e-07	272	37	6	31010829
Pubmed	The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.	PTEN FYN	1.10e-06	2	37	2	18339867
Pubmed	The Relationship between the Methylation of Promoter Regions of Tumor Suppressor Genes PTEN and APC with Endometrial Cancer.	APC PTEN	1.10e-06	2	37	2	31450893
Pubmed	Epithelial phosphatase and tensin homolog regulates intestinal architecture and secretory cell commitment and acts as a modifier gene in neoplasia.	APC PTEN	1.10e-06	2	37	2	19168705
Pubmed	Prevalence of APC and PTEN Alterations in Urachal Cancer.	APC PTEN	1.10e-06	2	37	2	32754865
Pubmed	Sonic Hedgehog promotes tumor cell survival by inhibiting CDON pro-apoptotic activity.	APC CDON	1.10e-06	2	37	2	23940460
Pubmed	Differential expression of tumor-associated genes and altered gut microbiome with decreased Akkermansia muciniphila confer a tumor-preventive microenvironment in intestinal epithelial Pten-deficient mice.	APC PTEN	1.10e-06	2	37	2	30292635
Pubmed	Construction of long-transcript enriched cDNA libraries from submicrogram amounts of total RNAs by a universal PCR amplification method.	APC TJP2 ARHGAP5 OAS1 CACNB2 VPS13B ZC3H13 MATR3 FRMPD1	1.52e-06	1084	37	9	11544199
Pubmed	The HIV-1 Tat protein recruits a ubiquitin ligase to reorganize the 7SK snRNP for transcriptional activation.	PHF2 TGM3 RNF2 PHF8 USP9Y FYN MATR3 ZNF287 EEF1A2	2.52e-06	1153	37	9	29845934
Pubmed	PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.	APC PTEN	3.30e-06	3	37	2	24293351
Pubmed	PHD finger protein 2 (PHF2) represses ribosomal RNA gene transcription by antagonizing PHF finger protein 8 (PHF8) and recruiting methyltransferase SUV39H1.	PHF2 PHF8	3.30e-06	3	37	2	25204660
Pubmed	Claudin 18 is a novel negative regulator of bone resorption and osteoclast differentiation.	TJP2 CLDN18	3.30e-06	3	37	2	22437732
Pubmed	Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin.	APC PTEN	3.30e-06	3	37	2	17693663
Pubmed	ZO-2 Suppresses Cell Migration Mediated by a Reduction in Matrix Metalloproteinase 2 in Claudin-18-Expressing Lung Adenocarcinoma A549 Cells.	TJP2 CLDN18	3.30e-06	3	37	2	30713254
Pubmed	eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer.	PTEN EEF1A2	3.30e-06	3	37	2	38442201
Pubmed	High-risk HPV infection modulates the promoter hypermethylation of APC, SFRP1, and PTEN in cervical cancer patients of North India.	APC PTEN	3.30e-06	3	37	2	33230782
Pubmed	Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.	APC PTEN	3.30e-06	3	37	2	21903772
Pubmed	Prostate cancer induced by loss of Apc is restrained by TGFβ signaling.	APC PTEN	3.30e-06	3	37	2	24651496
Pubmed	A functional network of the tumor suppressors APC, hDlg, and PTEN, that relies on recognition of specific PDZ-domains.	APC PTEN	3.30e-06	3	37	2	22434720
Pubmed	Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation.	APC PTEN	3.30e-06	3	37	2	19011632
Pubmed	Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse.	APC PTEN	3.30e-06	3	37	2	27538791
Pubmed	The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.	APC PTEN	6.60e-06	4	37	2	28174173
Pubmed	Effective combinatorial immunotherapy for penile squamous cell carcinoma.	APC PTEN	6.60e-06	4	37	2	32358507
Pubmed	Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis.	APC PTEN	6.60e-06	4	37	2	22922255
Pubmed	PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression.	APC PTEN	6.60e-06	4	37	2	23276799
Pubmed	Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma.	APC PTEN	6.60e-06	4	37	2	21062985
Pubmed	Targeting the histone demethylase PHF8-mediated PKCα-Src-PTEN axis in HER2-negative gastric cancer.	PHF8 PTEN	6.60e-06	4	37	2	32958674
Pubmed	Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.	APC PTEN	6.60e-06	4	37	2	23499052
Pubmed	Roles of tumor suppressors in regulating tumor-associated inflammation.	APC PTEN	6.60e-06	4	37	2	25190145
Pubmed	Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.	APC PTEN	6.60e-06	4	37	2	26279473
Pubmed	An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.	APC PTEN	6.60e-06	4	37	2	22214849
Pubmed	Apc inactivation, but not obesity, synergizes with Pten deficiency to drive intestinal stem cell-derived tumorigenesis.	APC PTEN	6.60e-06	4	37	2	28351943
Pubmed	Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.	APC PTEN	6.60e-06	4	37	2	17418409
Pubmed	MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.	APC PTEN	6.60e-06	4	37	2	24735923
Pubmed	Modulation of the canonical Wnt activity by androgen signaling in prostate epithelial basal stem cells.	APC PTEN	6.60e-06	4	37	2	37172587
Pubmed	HENA, heterogeneous network-based data set for Alzheimer's disease.	APC SORBS1 FYN MATR3	8.15e-06	120	37	4	31413325
Pubmed	A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon.	APC PTEN	1.10e-05	5	37	2	27536883
Pubmed	Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity.	APC PTEN	1.10e-05	5	37	2	19962666
Pubmed	Dual Roles of RNF2 in Melanoma Progression.	RNF2 PTEN	1.10e-05	5	37	2	26450788
Pubmed	TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis.	APC PTEN	1.10e-05	5	37	2	28484075
Pubmed	β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation.	APC PTEN	1.10e-05	5	37	2	20818428
Pubmed	c-Src drives intestinal regeneration and transformation.	APC FYN	1.10e-05	5	37	2	24788409
Pubmed	Tissue-Specific Effects of Reduced β-catenin Expression on Adenomatous Polyposis Coli Mutation-Instigated Tumorigenesis in Mouse Colon and Ovarian Epithelium.	APC PTEN	1.65e-05	6	37	2	26528816
Pubmed	HUWE1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation.	APC PTEN	1.65e-05	6	37	2	28003334
Pubmed	A tumour-resident Lgr5+ stem-cell-like pool drives the establishment and progression of advanced gastric cancers.	APC CLDN18	1.65e-05	6	37	2	34857912
Pubmed	Tumor suppression by miR-26 overrides potential oncogenic activity in intestinal tumorigenesis.	APC PTEN	1.65e-05	6	37	2	25395662
Pubmed	Wnt ligands influence tumour initiation by controlling the number of intestinal stem cells.	APC PTEN	1.65e-05	6	37	2	29556067
Pubmed	Defining the role of APC in the mitotic spindle checkpoint in vivo: APC-deficient cells are resistant to Taxol.	APC PTEN	1.65e-05	6	37	2	20729907
Pubmed	The human cytoplasmic dynein interactome reveals novel activators of motility.	APC TJP2 ARHGAP5 TGM3 SORBS1 PHF8 AASS	2.82e-05	853	37	7	28718761
Pubmed	Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.	APC PTEN	3.07e-05	8	37	2	24823640
Pubmed	Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin ligase activators Ndfip1 and Ndfip2.	PTEN FYN	3.07e-05	8	37	2	20534535
Pubmed	RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China.	APC PTEN	3.95e-05	9	37	2	19506903
Pubmed	Integrated β-catenin, BMP, PTEN, and Notch signalling patterns the nephron.	APC PTEN	3.95e-05	9	37	2	25647637
Pubmed	AQP5 enriches for stem cells and cancer origins in the distal stomach.	APC PTEN	3.95e-05	9	37	2	32025032
Pubmed	Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines.	APC PTEN	3.95e-05	9	37	2	39128004
Pubmed	Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.	APC PTEN	4.93e-05	10	37	2	23610450
Pubmed	Identification of novel Ack1-interacting proteins and Ack1 phosphorylated sites in mouse brain by mass spectrometry.	TJP2 SORBS1 MATR3	5.07e-05	67	37	3	29254152
Pubmed	A myelin-related transcriptomic profile is shared by Pitt-Hopkins syndrome models and human autism spectrum disorder.	APC PTEN	6.02e-05	11	37	2	32015540
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	SORBS1 PHF8 VPS13B FRMPD1 LARGE1	6.86e-05	407	37	5	12693553
Pubmed	Mouse models in tumor suppression.	APC PTEN	7.22e-05	12	37	2	9917000
Pubmed	A phospho/methyl switch at histone H3 regulates TFIID association with mitotic chromosomes.	PHF2 PHF8	8.53e-05	13	37	2	20953165
Pubmed	Genotype phenotype correlations in Israeli colorectal cancer patients.	APC PTEN	8.53e-05	13	37	2	15523694
Pubmed	Constitutional mislocalization of Pten drives precocious maturation in oligodendrocytes and aberrant myelination in model of autism spectrum disorder.	APC PTEN	8.53e-05	13	37	2	30664625
Pubmed	Ex vivo Quantitative Proteomic Analysis of Serotonin Transporter Interactome: Network Impact of the SERT Ala56 Coding Variant.	APC TJP2 SORBS1 RUNDC3A FRMPD1	8.88e-05	430	37	5	32581705
Pubmed	Comprehensive identification of phosphorylation sites in postsynaptic density preparations.	TJP2 SORBS1 MATR3 EEF1A2	1.05e-04	231	37	4	16452087
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	APC TMOD3 TJP2 ARHGAP5 CACNB2 SORBS1 MATR3 EEF1A2	1.07e-04	1431	37	8	37142655
Pubmed	Integrin signalling regulates YAP and TAZ to control skin homeostasis.	APC FYN	1.15e-04	15	37	2	26989177
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	PHF2 CACNB2 PTEN RASA3 SUPT6H VPS13B FRMPD1 EEF1A2	1.41e-04	1489	37	8	28611215
Pubmed	Molecular genetics of successful smoking cessation: convergent genome-wide association study results.	GALNTL6 CACNB2 LARGE1	1.72e-04	101	37	3	18519826
Pubmed	RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.	EFR3B APC VPS13B MATR3	1.73e-04	263	37	4	34702444
Pubmed	Genome-wide association study of primary tooth eruption identifies pleiotropic loci associated with height and craniofacial distances.	CACNB2 CDON	2.07e-04	20	37	2	23704328
Pubmed	Nuclear organization of nucleotide excision repair is mediated by RING1B dependent H2A-ubiquitylation.	RNF2 MATR3 EEF1A2	2.33e-04	112	37	3	28416769
Pubmed	Neither replication nor simulation supports a role for the axon guidance pathway in the genetics of Parkinson's disease.	MRAS FYN	2.51e-04	22	37	2	18628988
Pubmed	Hes genes regulate size, shape and histogenesis of the nervous system by control of the timing of neural stem cell differentiation.	CLDN18 RAX	2.51e-04	22	37	2	15496443
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	APC TJP2 SORBS1 AASS MATR3 EEF1A2	2.73e-04	861	37	6	36931259
Pubmed	Large-scale concatenation cDNA sequencing.	EFR3B APC RUNDC3A SUPT6H MATR3	3.23e-04	568	37	5	9110174
Pubmed	RBX2 maintains final retinal cell position in a DAB1-dependent and -independent fashion.	FYN RAX	3.25e-04	25	37	2	29361558
Pubmed	Identification of preferred protein interactions by phage-display of the human Src homology-3 proteome.	SORBS1 FYN	3.25e-04	25	37	2	16374509
Pubmed	A "double adaptor" method for improved shotgun library construction.	EFR3B APC RUNDC3A SUPT6H MATR3	3.39e-04	574	37	5	8619474
Pubmed	Olig1 function is required to repress dlx1/2 and interneuron production in Mammalian brain.	APC TFAP2B	3.52e-04	26	37	2	24507192
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	APC RIOK3 SORBS1 SUPT6H VPS50	3.79e-04	588	37	5	38580884
Pubmed	Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.	TJP2 FYN ZC3H13	3.86e-04	133	37	3	15144186
Pubmed	Scribble is required for normal epithelial cell-cell contacts and lumen morphogenesis in the mammalian lung.	TJP2 CLDN18	4.09e-04	28	37	2	23195221
Pubmed	Genetic mapping of eight SH3 domain genes on seven mouse chromosomes.	CACNB2 SORBS1	4.09e-04	28	37	2	10087302
Pubmed	Transferrin Receptor Protein 1 Cooperates with mGluR2 To Mediate the Internalization of Rabies Virus and SARS-CoV-2.	PHF2 TMOD3 RNF2 MATR3	4.25e-04	333	37	4	36779763
Pubmed	WWP2 ubiquitylates RNA polymerase II for DNA-PK-dependent transcription arrest and repair at DNA breaks.	RNF2 PHF8 SUPT6H MATR3 EEF1A2	4.64e-04	615	37	5	31048545
Pubmed	Integrin linked kinase (ILK) is required for lens epithelial cell survival, proliferation and differentiation.	ARHGAP5 PTEN	4.70e-04	30	37	2	24472646
Pubmed	NFX1-123 and poly(A) binding proteins synergistically augment activation of telomerase in human papillomavirus type 16 E6-expressing cells.	MATR3 EEF1A2	5.35e-04	32	37	2	17267499
Pubmed	Association of mitotic regulation pathway polymorphisms with pancreatic cancer risk and outcome.	APC FYN	5.35e-04	32	37	2	20056645
Pubmed	Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin.	TMOD3 OAS1 EEF1A2	5.38e-04	149	37	3	26370502
Pubmed	ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair.	RNF2 SUPT6H MATR3	5.49e-04	150	37	3	28242625
Pubmed	Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM.	PHF2 PHF8	5.69e-04	33	37	2	26864203
Pubmed	Ubiquitin-Independent Disassembly by a p97 AAA-ATPase Complex Drives PP1 Holoenzyme Formation.	APC TMOD3 SUPT6H ZC3H13	5.75e-04	361	37	4	30344098
Pubmed	Endogenous Cell Type-Specific Disrupted in Schizophrenia 1 Interactomes Reveal Protein Networks Associated With Neurodevelopmental Disorders.	TMOD3 TJP2 MATR3	6.15e-04	156	37	3	29961565
Pubmed	Genomic analysis of mouse retinal development.	APC CACNB2 RASA3 RAX IMPG2 LARGE1	6.23e-04	1006	37	6	15226823
Pubmed	Analysis of phosphatase and tensin homolog tumor suppressor interacting proteins by in vitro and in silico proteomics.	PTEN EEF1A2	6.78e-04	36	37	2	15717329
Pubmed	Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic development.	PTEN FYN	6.78e-04	36	37	2	22422068
Pubmed	A bead-based approach for large-scale identification of in vitro kinase substrates.	TMOD3 SUPT6H ZC3H13	6.99e-04	163	37	3	22113938
Pubmed	Telencephalic embryonic subtractive sequences: a unique collection of neurodevelopmental genes.	RNF2 MATR3 CDON	7.24e-04	165	37	3	16107646
Pubmed	Human variation in alcohol response is influenced by variation in neuronal signaling genes.	CACNB2 SORBS1 LARGE1	8.02e-04	171	37	3	20201926
Interaction	CTNNB1 interactions	APC TMOD3 TJP2 ARHGAP5 SORBS1 PTEN FYN AASS MATR3 CDON	7.31e-06	1009	36	10	int:CTNNB1
Interaction	DDX23 interactions	PHF2 TJP2 PHF8 FYN SUPT6H ZC3H13 MATR3	1.91e-05	480	36	7	int:DDX23
Cytoband	3q22.3	CLDN18 MRAS	1.87e-04	25	37	2	3q22.3
GeneFamily	PHD finger proteins\|Lysine demethylases	PHF2 PHF8	4.20e-04	24	23	2	485
GeneFamily	Calcium voltage-gated channel subunits\|Membrane associated guanylate kinases	TJP2 CACNB2	4.94e-04	26	23	2	904
GeneFamily	PHD finger proteins	PHF2 PHF8	5.79e-03	90	23	2	88
GeneFamily	SH2 domain containing	FYN SUPT6H	7.24e-03	101	23	2	741
GeneFamily	PDZ domain containing	TJP2 FRMPD1	1.58e-02	152	23	2	1220
ToppCell	RV-03._Atrial_Cardiomyocyte\|RV / Chamber and Cluster_Paper	CACNB2 SORBS1 MATR3 LARGE1	1.74e-06	105	37	4	49e16b11f16e83a7d17d162c14bce991201bcc2a
ToppCell	critical-Lymphoid-NK\|critical / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	EFR3B GALNTL6 SORBS1 TFAP2B	1.48e-05	180	37	4	5abf778395392244daaec876f306ed7e4f388686
ToppCell	RV\|World / Chamber and Cluster_Paper	GALNTL6 CACNB2 SORBS1 LARGE1	1.51e-05	181	37	4	bbe1e6e59d8889bd37d6e8303116cbdcafca7236
ToppCell	NS-critical-d_07-13-Lymphoid-NK\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	EFR3B GALNTL6 SORBS1 TFAP2B	1.54e-05	182	37	4	dd1c59babf7211362452e3e264009d70004d99f6
ToppCell	PCW_05-06-Neuronal-Neuronal_postreplicative-neuro_immature_neuronal_(2)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	RUNDC3A TFAP2B FRMPD1 EEF1A2	1.57e-05	183	37	4	9dfb398b9995d562864fe688861a831ada0814cd
ToppCell	wk_08-11-Epithelial-PNS-MFNG+_DBH+_neuron\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	RUNDC3A TFAP2B FRMPD1 EEF1A2	1.75e-05	188	37	4	d3d7d21d4fa39ac4106a164652673de1bef8662d
ToppCell	5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.3\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ARHGAP5 OAS1 RIOK3 EEF1A2	1.86e-05	191	37	4	fbd8d337b4444fba8527a614e4a8bfb516ce0f66
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	CACNB2 FYN AASS AOX1	1.94e-05	193	37	4	261cafc167c86ab277be4ea7f08b0173e2dde26e
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	CACNB2 AASS CDON AOX1	2.02e-05	195	37	4	ff0aa455e9844a6d7ae57ff59fb6cea825cf1fc2
ToppCell	Parenchymal-10x5prime-Stromal-Mesofibroblastic\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CACNB2 CDON AOX1 EEF1A2	2.10e-05	197	37	4	88a86286b9c3ea3b076d7464faec42d0392ee7f8
ToppCell	Parenchymal-10x5prime-Stromal-Mesofibroblastic-Mesothelia\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CACNB2 CDON AOX1 EEF1A2	2.10e-05	197	37	4	2773d2eb5f232a7e49da116efffcb6bf5eb90810
ToppCell	Macroglial-Astrocytes-SLC14A1\|Macroglial / cells hierarchy compared to all cells using T-Statistic	EFR3B CACNB2 ETNPPL SORBS1	2.23e-05	200	37	4	16f468217427921fa18c6d078ffa990eb019b257
ToppCell	Macroglial-Astrocytes\|Macroglial / cells hierarchy compared to all cells using T-Statistic	EFR3B CACNB2 ETNPPL SORBS1	2.23e-05	200	37	4	941536b7c32f1e63c70535233b2ccce0cd7bf96e
ToppCell	Macroglial-Astrocytes-SLC14A1---\|Macroglial / cells hierarchy compared to all cells using T-Statistic	EFR3B CACNB2 ETNPPL SORBS1	2.23e-05	200	37	4	d6fcbf4f4bc1b89a9929d7b114c6b907b6979900
ToppCell	Macroglial-Astrocytes-SLC14A1----L1-6\|Macroglial / cells hierarchy compared to all cells using T-Statistic	EFR3B CACNB2 ETNPPL SORBS1	2.23e-05	200	37	4	f861509b54185d89931db64da1b9d81986cc7938
ToppCell	Parenchyma_COVID-19-Stromal-TX-Mesothelial-1\|Parenchyma_COVID-19 / Sample group, Lineage and Cell type	ETNPPL CDON AOX1 EEF1A2	2.23e-05	200	37	4	bf50e30d5cafb71c567e89580f62084d2f894170
ToppCell	Macroglial-Astrocytes-SLC14A1--\|Macroglial / cells hierarchy compared to all cells using T-Statistic	EFR3B CACNB2 ETNPPL SORBS1	2.23e-05	200	37	4	0442894c39eec69850c090957a5dc7bcecd21e04
ToppCell	Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Mesothelial-1-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	ETNPPL CDON AOX1 EEF1A2	2.23e-05	200	37	4	5e5ad07679d5dd2ca80249bce9aaf4a95d42187b
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Astrocyte-Astrocyte-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	APC CACNB2 ETNPPL SORBS1	2.23e-05	200	37	4	07d942803360e1a1e8e131d6e31c726dd0db1a0b
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Astrocyte-Astrocyte\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	APC CACNB2 ETNPPL SORBS1	2.23e-05	200	37	4	d0812817ef99608994193787a62d39adeb2070ca
ToppCell	Macroglial-Astrocytes-SLC14A1-\|Macroglial / cells hierarchy compared to all cells using T-Statistic	EFR3B CACNB2 ETNPPL SORBS1	2.23e-05	200	37	4	01819446deeab9054f5cfe889d53bb49d137dbc0
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Astrocyte\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	APC CACNB2 ETNPPL SORBS1	2.23e-05	200	37	4	cd54ddf1919c98e84b7e4aba85b374fc8b407206
ToppCell	Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Mesothelial-1\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	ETNPPL CDON AOX1 EEF1A2	2.23e-05	200	37	4	c800f20adedf4ca736c740510889e92d8bf0ba44
ToppCell	Globus_pallidus-Macroglia-ASTROCYTE-Gja1\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	ETNPPL AASS RAX	1.07e-04	111	37	3	7d7aad8e9811c67fb9abfb4ebc75def01a517adf
ToppCell	Globus_pallidus-Macroglia-ASTROCYTE\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	ETNPPL AASS RAX	1.07e-04	111	37	3	cb45322fbeafec2f1ab7a3727da69abb1047567d
ToppCell	Posterior_cortex-Macroglia-ASTROCYTE\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	ETNPPL AASS RAX	1.10e-04	112	37	3	1c0bcc6c972c50a9d950cd56b65efb8d778ec25a
ToppCell	Posterior_cortex-Macroglia-ASTROCYTE-Gja1\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	ETNPPL AASS RAX	1.10e-04	112	37	3	e30cd0b7b755c63081bbeed4e1a884b6640d34f8
ToppCell	PBMC-Control-Hematopoietic-RBC\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CLDN18 RUNDC3A MATR3	1.28e-04	118	37	3	e1fb21a8ec0f7b8b828d12e5dc8b470dbf3dc810
ToppCell	PBMC-Control-Hematopoietic-RBC-RBC\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CLDN18 RUNDC3A MATR3	1.28e-04	118	37	3	25d35c13d51a347e305f3a3ce239800cf118848e
ToppCell	PBMC-Control-Hematopoietic-RBC-RBC-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CLDN18 RUNDC3A MATR3	1.28e-04	118	37	3	68a891a0597d206ad5f66c6e087126f020e972b5
ToppCell	Hippocampus-Macroglia-ASTROCYTE-Gja1\|Hippocampus / BrainAtlas - Mouse McCarroll V32	ETNPPL AASS RAX	1.31e-04	119	37	3	79342c491a214c870ff6215da613db4a28c9d587
ToppCell	Hippocampus-Macroglia-ASTROCYTE\|Hippocampus / BrainAtlas - Mouse McCarroll V32	ETNPPL AASS RAX	1.31e-04	119	37	3	36857095d4e4cc6428d13bf7de04daec1f4cde1e
ToppCell	LV-03._Atrial_Cardiomyocyte\|LV / Chamber and Cluster_Paper	CACNB2 SORBS1 LARGE1	1.35e-04	120	37	3	3b77bd0e3630cdd45001cecf5e47660a90ebc92e
ToppCell	RV-03._Atrial_Cardiomyocyte\|World / Chamber and Cluster_Paper	CACNB2 SORBS1 LARGE1	1.41e-04	122	37	3	1cb1dd03b2aaedbe04f3ed907568c3b7f54767b3
ToppCell	LV-03._Atrial_Cardiomyocyte\|World / Chamber and Cluster_Paper	CACNB2 SORBS1 LARGE1	1.70e-04	130	37	3	a3e12984fb61311e49cc76c59f74f4dffc48faa1
ToppCell	TCGA-Testes-Primary_Tumor-Testicular_Germ_Cell_Tumor-Non-Seminoma-_Embryonal_Carcinoma-1\|TCGA-Testes / Sample_Type by Project: Shred V9	TJP2 AASS MATR3	1.86e-04	134	37	3	d80c9168acbd316761330d29e994e7f9a30ad945
ToppCell	(08)_Brush+PNEC-(2)_GFP_FOXI1\|(08)_Brush+PNEC / shred by cell type by condition	APC OAS1 ZC3H13	2.03e-04	138	37	3	817e3f639604ea95adae01e8685ffaa2e0aff7a8
ToppCell	primary_visual_cortex-Non-neuronal-astrocyte\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ETNPPL AASS AOX1	2.75e-04	153	37	3	95b28c5bd10ffb74c0993ebd565038b9818e4bd2
ToppCell	primary_visual_cortex-Non-neuronal-astrocyte-Astro\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ETNPPL AASS AOX1	2.75e-04	153	37	3	b09f8def40a1ea56722f3398f61a036667b61cd9
ToppCell	primary_visual_cortex-Non-neuronal-astrocyte-Astro-Astro_Aqp4\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ETNPPL AASS AOX1	2.75e-04	153	37	3	3ab9d55b3db51715c1d61eca142384195ce4b54f
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	TJP2 CACNB2 AASS	2.81e-04	154	37	3	b6e982e341c6cfb6ff80a318078fcb10c36d182f
ToppCell	facs-Brain_Non-Myeloid-Hippocampus_-18m-Macroglial-astrocyte\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MRAS AASS AOX1	2.81e-04	154	37	3	5ed64bbf603290e6dc34f81d145982690b89dd0d
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	TJP2 CACNB2 AASS	2.81e-04	154	37	3	d76fd51a4587decbfe1dde1c8a9b880c5fa18e4a
ToppCell	frontal_cortex-Non-neuronal-astrocyte\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ETNPPL AASS AOX1	2.97e-04	157	37	3	803af734d7f775d294391e2b84e472a732e18cef
ToppCell	frontal_cortex-Non-neuronal-astrocyte-Astro-Astro_Aqp4\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ETNPPL AASS AOX1	2.97e-04	157	37	3	9aa5304a9704da6dd4eda7d6940494b00e38b2e8
ToppCell	frontal_cortex-Non-neuronal-astrocyte-Astro\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ETNPPL AASS AOX1	2.97e-04	157	37	3	0551442ae14685d8fe5729e3960c6324b1e05e4d
ToppCell	P15-Epithelial-epithelial_progenitor_cell-epi_progenitor\|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	CLDN18 ETNPPL AASS	3.08e-04	159	37	3	a4bfd59c53237964fc24a24de5c1925fdd01db99
ToppCell	severe_influenza-cDC\|severe_influenza / disease group, cell group and cell class (v2)	GALNTL6 CACNB2 MATR3	3.20e-04	161	37	3	7716315b8bda904b346cea47edc2c0b507a345c2
ToppCell	5'-GW_trimst-2-LargeIntestine-Epithelial-neuro-epithelial-EECs\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CACNB2 RUNDC3A AOX1	3.43e-04	165	37	3	4b4e75ad0eb0a6b00c30a000ec6267e23ba2e496
ToppCell	3'-Distal_airway-Immune_Lymphocytic-Lymphocytic_B-B_cell-B_cells\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	GALNTL6 ETNPPL EEF1A2	3.49e-04	166	37	3	a8ba4d51e778634f8a7f47fa0d01a2019f774fb8
ToppCell	3'-Distal_airway-Immune_Lymphocytic-Lymphocytic_B-B_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	GALNTL6 ETNPPL EEF1A2	3.49e-04	166	37	3	4906c85f52c3751166e296102d524a13b1f438f5
ToppCell	3'-Distal_airway-Immune_Lymphocytic-Lymphocytic_B-B_cell-B_cells-B_cells_L.1.5.0.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	GALNTL6 ETNPPL EEF1A2	3.49e-04	166	37	3	04e32bd32165cdf316f2a8709c3662d55cd70391
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c03-GZMK\|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)	RNF2 FYN FRMPD1	3.49e-04	166	37	3	9e916fc1858573358e1eb5e3789b2c9f8ef74476
ToppCell	TCGA-Brain-Primary_Tumor-Low_Grade_Glioma-Astrocytoma-9\|TCGA-Brain / Sample_Type by Project: Shred V9	TJP2 ETNPPL SORBS1	3.56e-04	167	37	3	013971700e80b71e4b8c79b8fff0d8beeac295c3
ToppCell	Adult-Mesenchymal-vascular_smooth_muscle_cell-D175\|Adult / Lineage, Cell type, age group and donor	CACNB2 SORBS1 MATR3	3.56e-04	167	37	3	c4e321bb87512ea839f324c92c0f1afea891483f
ToppCell	TCGA-Endometrium-Solid_Tissue_Normal-Endometrium_normal_tissue-Endometrium-7\|TCGA-Endometrium / Sample_Type by Project: Shred V9	CACNB2 SORBS1 AOX1	3.62e-04	168	37	3	a97e8e07ba949b30805aeed5f60fa5e092b9d3d4
ToppCell	3'-GW_trimst-2-LargeIntestine-Epithelial-neuro-epithelial\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGM3 CACNB2 RUNDC3A	3.62e-04	168	37	3	38ba7737ae0afffcbd3aa499403e83c24a922127
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-hematologic-erythrocytic-erythroid_lineage_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	RIOK3 RUNDC3A RAX	3.75e-04	170	37	3	288014dedda8babc51fe08e48a55e68d83e1b1d2
ToppCell	3'-Child09-12-SmallIntestine-Epithelial-neuro-epithelial-N_cells_(NTS+)\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGM3 RUNDC3A AOX1	3.75e-04	170	37	3	02f0be0aab8ba2d35a83238609352ef3677511c9
ToppCell	TCGA-Endometrium-Solid_Tissue_Normal-Endometrium_normal_tissue-Endometrium\|TCGA-Endometrium / Sample_Type by Project: Shred V9	CACNB2 SORBS1 AOX1	3.75e-04	170	37	3	cdc19013da7c41d1ed8400a6a643e4c684ff9912
ToppCell	TCGA-Endometrium-Solid_Tissue_Normal\|TCGA-Endometrium / Sample_Type by Project: Shred V9	CACNB2 SORBS1 AOX1	3.75e-04	170	37	3	0bde0a40440c7fdf7ba89cac8831d4014e7a4807
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c03-ITGA4\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	ARHGAP5 FYN AASS	3.75e-04	170	37	3	adb625124832b0786a590e8f75b61e7263a1e0d4
ToppCell	TCGA-Endometrium-Solid_Tissue_Normal-Endometrium_normal_tissue\|TCGA-Endometrium / Sample_Type by Project: Shred V9	CACNB2 SORBS1 AOX1	3.75e-04	170	37	3	516b38c4ecf6b0b04c5d4f80c510dcc00b328c6f
ToppCell	3'-Child04-06-SmallIntestine-Epithelial-neuro-epithelial\|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGM3 RUNDC3A AOX1	3.94e-04	173	37	3	07798461d12d04f3dabff03481c999cb07c5af2f
ToppCell	3'-Child04-06-SmallIntestine-Epithelial-neuro-epithelial-EC_cells_(TAC1+)\|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGM3 RUNDC3A CDON	4.01e-04	174	37	3	a62531ebf16b32b249168dca11b870f63a8aa81c
ToppCell	5'-Adult-LargeIntestine-Epithelial-neuro-epithelial-EC_cells_(TAC1+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGM3 CACNB2 RUNDC3A	4.08e-04	175	37	3	182e45f5c02214d6b9f317ff5dc43af8b42de978
ToppCell	10x_3'_v2v3-Neoplastic-Differentiated-like-MES-like-MES-like_hypoxia/MHC-B\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TJP2 SORBS1 EEF1A2	4.08e-04	175	37	3	e99e145a152f534b75267ec492a252a0b814b4f8
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D122\|Adult / Lineage, Cell type, age group and donor	USP9Y TFAP2B AASS	4.15e-04	176	37	3	3fee8a367bb9755aca1b7fcc968b08e51b6e9436
ToppCell	3'-Child09-12-SmallIntestine-Epithelial-neuro-epithelial\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGM3 RUNDC3A AOX1	4.15e-04	176	37	3	2e1003dc373b14d27f0464d980453fdcfc1005f0
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CACNB2 PTEN LARGE1	4.22e-04	177	37	3	a8625d14682183cf77cb51eaf11bc15a3528f586
ToppCell	3'-Adult-LargeIntestine-Hematopoietic-T_cells-SELL+_CD4_T\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RASA3 FYN ZNF287	4.22e-04	177	37	3	bb496fbec7cacc52847abe2b2714249c47879763
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CACNB2 FYN LARGE1	4.22e-04	177	37	3	4d2cdb57b427a42085c5f9affa0967b15e84dec3
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CACNB2 PTEN LARGE1	4.22e-04	177	37	3	3645e2f4a48283f290f85c49c3e79e3f58ac9aa6
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_2\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CLDN18 ARHGAP5 USP9Y	4.22e-04	177	37	3	c9e8149639551a4c8daa90fcb2b895fdcff2e2ba
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CACNB2 FYN LARGE1	4.29e-04	178	37	3	edc7143dc9959d36057cb9471681a23afcbc8cce
ToppCell	droplet-Marrow-nan-3m-Lymphocytic-nan\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	APC ARHGAP5 FYN	4.36e-04	179	37	3	87a69f9f83b8f0c028a4874acb238f2e079bf51f
ToppCell	droplet-Marrow-nan-3m-Lymphocytic\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	APC ARHGAP5 FYN	4.36e-04	179	37	3	dcaf2191134a586d50ebaf67dcf5b815b54a722b
ToppCell	COPD-Stromal-SMC\|World / Disease state, Lineage and Cell class	CACNB2 SORBS1 AASS	4.36e-04	179	37	3	b2709537ec1b46457ab85261f4cdd354e60a8b29
ToppCell	3'_v3-bone_marrow-Myeloid_Mac-Erythrophagocytic_macrophages\|bone_marrow / Manually curated celltypes from each tissue	OAS1 MRAS VPS50	4.43e-04	180	37	3	daf69a548ed7c6f285a6adcff00f99aa22f9d6a5
ToppCell	facs-Marrow-B-cells-3m-Myeloid-CD4+_macrophage\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	APC ARHGAP5 FYN	4.43e-04	180	37	3	bf8d13d4db1af55b8c9fe16aaccf8743e000e005
ToppCell	facs-Marrow-B-cells-3m-Myeloid\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	APC ARHGAP5 FYN	4.43e-04	180	37	3	839defb40f7cfb2711e9025194de636533f51bcd
ToppCell	facs-Marrow-B-cells-3m-Myeloid-macrophage\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	APC ARHGAP5 FYN	4.43e-04	180	37	3	82965ed1b72a1873c24dd4553d39681596057316
ToppCell	droplet-Marrow-nan-3m-Lymphocytic-precursor_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	APC ARHGAP5 FYN	4.43e-04	180	37	3	df60970520fba2ac0639faa54096766d07418ca4
ToppCell	5'-GW_trimst-2-LargeIntestine-Epithelial-neuro-epithelial-EC_cells_(NPW+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGM3 CACNB2 RUNDC3A	4.50e-04	181	37	3	2392af8c7f040c23a7d416c2e37419954970c8f4
ToppCell	COVID-19-Heart-CM_+_EC_+_Pericyte\|COVID-19 / Disease (COVID-19 only), tissue and cell type	CACNB2 SORBS1 LARGE1	4.50e-04	181	37	3	719eb532453ab7cd7893726885bc75d74a10b21e
ToppCell	5'-GW_trimst-2-LargeIntestine-Epithelial-neuro-epithelial\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGM3 CACNB2 RUNDC3A	4.57e-04	182	37	3	0e589bf97d51b4b2f723f8c45853ad81b7ce8778
ToppCell	wk_20-22-Hematologic-Meg-ery-Definitive_erythroblast\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	GALNTL6 RIOK3 RUNDC3A	4.57e-04	182	37	3	0c77ef4556c1d1512ebe9077df858b28f9e38dd5
ToppCell	PSB-critical-LOC-Epithelial-Squamous\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	RIOK3 TGM3 EEF1A2	4.65e-04	183	37	3	2cf798a2371c61322484ea16fdfae0acfa94f102
ToppCell	10x_3'_v2v3-Neoplastic-Stem-like-NPC-like-NPC-like_OPC-G\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	RUNDC3A FYN RAX	4.65e-04	183	37	3	8c8ce5a0d5535bef58ac10b7eb726f9c50af2ed8
ToppCell	wk_08-11-Epithelial-PNS-PCP4+_neuron\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	TFAP2B FRMPD1 EEF1A2	4.72e-04	184	37	3	eac2a9089913f33a961ba11519b53645790f2056
ToppCell	LV-15._Ventricular_Cardiomyocyte_III\|LV / Chamber and Cluster_Paper	CACNB2 SORBS1 LARGE1	4.72e-04	184	37	3	ab7a1620c14a9d9b6be1b47c559931e345e9eef8
ToppCell	droplet-Spleen-nan-18m-Lymphocytic-T_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TJP2 ARHGAP5 FYN	4.72e-04	184	37	3	8c23945bafe8926f25836bc208115edd5214a2b0
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	ARHGAP5 RASA3 FYN	4.72e-04	184	37	3	bd786db4dc4edae6d5cfc0b69901983dea19f729
ToppCell	COVID-19-Heart-CM_2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	CACNB2 SORBS1 LARGE1	4.79e-04	185	37	3	549eeb521c3985bff396ea0f202db21822efa51f
ToppCell	Fetal_29-31_weeks-Mesenchymal-airway_smooth_muscle_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	SORBS1 RASA3 LARGE1	4.79e-04	185	37	3	e58a009aaf342be019a909747b1895d5987d4daf
ToppCell	LV-15._Ventricular_Cardiomyocyte_III\|World / Chamber and Cluster_Paper	CACNB2 SORBS1 LARGE1	4.79e-04	185	37	3	6baccb26f999145e51b91d94315bf8d4655bef31
ToppCell	wk_20-22-Hematologic-Meg-ery-Definitive_reticulocyte\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	GALNTL6 RIOK3 RUNDC3A	4.79e-04	185	37	3	4a2c85e292d4cbce80e92992ded5d66a3aa446ee
ToppCell	COPD-Epithelial-Mesothelial\|World / Disease state, Lineage and Cell class	TJP2 CACNB2 AOX1	4.79e-04	185	37	3	23579988036fc1925992c31919750f9b3fe9f790
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	CACNB2 FYN LARGE1	4.79e-04	185	37	3	9197f074e769d54031ec41abfc65fcc0c6552c7e
ToppCell	PCW_05-06-Neuronal-Neuronal_postreplicative\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	RUNDC3A TFAP2B EEF1A2	4.79e-04	185	37	3	512f489daeb3b72d4578dc6f4d0ebb5f38d5bbab
Drug	Gramine [87-52-5]; Up 200; 23uM; MCF7; HT_HG-U133A	SORBS1 RASA3 FYN TFAP2B AOX1 FRMPD1	6.41e-07	193	37	6	4118_UP
Drug	estradiol; Up 200; 0.01uM; PC3; HT_HG-U133A	OAS1 CACNB2 SORBS1 RASA3 VPS13B FRMPD1	7.02e-07	196	37	6	5910_UP
Drug	Cyproheptadine hydrochloride [969-33-5]; Up 200; 12.4uM; PC3; HT_HG-U133A	CLDN18 OAS1 RUNDC3A MRAS RASA3 LARGE1	7.02e-07	196	37	6	6740_UP
Drug	Carbenoxolone disodium salt [7421-40-1]; Up 200; 6.6uM; MCF7; HT_HG-U133A	EFR3B APC SORBS1 RUNDC3A USP9Y ZC3H13	7.67e-07	199	37	6	3353_UP
Drug	Lobeline alpha (-) hydrochoride [134-63-4]; Down 200; 10.6uM; PC3; HT_HG-U133A	APC SORBS1 RNF2 PHF8 AASS IMPG2	7.67e-07	199	37	6	5784_DN
Drug	15d-PGJ2; Up 200; 10uM; PC3; HT_HG-U133A	OAS1 SORBS1 RUNDC3A RNF2 FRMPD1	1.12e-05	183	37	5	4455_UP
Drug	Mephentermine hemisulfate [1212-72-2]; Up 200; 9.4uM; MCF7; HT_HG-U133A	APC OAS1 MRAS RASA3 ZC3H13	1.18e-05	185	37	5	4707_UP
Drug	Antipyrine, 4-hydroxy [1672-63-5]; Up 200; 19.6uM; MCF7; HT_HG-U133A	APC OAS1 RUNDC3A MRAS RASA3	1.42e-05	192	37	5	4175_UP
Drug	Amprolium hydrochloride [137-88-2]; Down 200; 12.6uM; PC3; HT_HG-U133A	RUNDC3A FYN AASS CDON FRMPD1	1.45e-05	193	37	5	4241_DN
Drug	Imidurea [39236-46-9]; Up 200; 10.4uM; MCF7; HT_HG-U133A	OAS1 CACNB2 PHF8 TFAP2B VPS50	1.53e-05	195	37	5	3522_UP
Drug	estradiol, USP; Up 200; 0.1uM; MCF7; HT_HG-U133A	APC RUNDC3A USP9Y FYN TFAP2B	1.53e-05	195	37	5	5568_UP
Drug	Selegiline hydrochloride [14611-52-0]; Up 200; 17.8uM; MCF7; HT_HG-U133A	CACNB2 SORBS1 RUNDC3A RASA3 VPS50	1.60e-05	197	37	5	2826_UP
Drug	(S)-(-)-Cycloserine [339-72-0]; Down 200; 39.2uM; MCF7; HT_HG-U133A	APC CACNB2 FYN VPS50 AOX1	1.60e-05	197	37	5	3870_DN
Drug	Flucloxacillin sodium [1847-24-1]; Up 200; 8.4uM; PC3; HT_HG-U133A	APC OAS1 CACNB2 AASS FRMPD1	1.64e-05	198	37	5	5102_UP
Drug	(S)-(-)-Atenolol [93379-54-5]; Down 200; 15uM; PC3; HT_HG-U133A	SORBS1 RNF2 AASS CDON FRMPD1	1.64e-05	198	37	5	6725_DN
Drug	Nadolol [42200-33-9]; Up 200; 13uM; MCF7; HT_HG-U133A	EFR3B RNF2 RASA3 FYN ZC3H13	1.64e-05	198	37	5	3359_UP
Drug	Niacin [59-67-6]; Up 200; 32.4uM; PC3; HT_HG-U133A	APC OAS1 FYN SUPT6H FRMPD1	1.64e-05	198	37	5	6702_UP
Drug	Naphazoline hydrochloride [550-99-2]; Up 200; 16.2uM; PC3; HT_HG-U133A	OAS1 SUPT6H VPS50 IMPG2 FRMPD1	1.64e-05	198	37	5	6604_UP
Drug	Prazosin hydrochloride [19237-84-4]; Up 200; 9.6uM; MCF7; HT_HG-U133A	SORBS1 AASS ZC3H13 CDON IMPG2	1.64e-05	198	37	5	5416_UP
Drug	Liothyronine [6893-02-3]; Up 200; 6.2uM; MCF7; HT_HG-U133A	CLDN18 RASA3 FYN ZNF287 IMPG2	1.64e-05	198	37	5	3324_UP
Drug	Bezafibrate [41859-67-0]; Up 200; 11uM; MCF7; HT_HG-U133A	APC TFAP2B ZNF287 CDON IMPG2	1.64e-05	198	37	5	4999_UP
Drug	Acetopromazine maleate salt [3598-37-6]; Up 200; 9uM; PC3; HT_HG-U133A	FYN TFAP2B ZNF287 IMPG2 FRMPD1	1.68e-05	199	37	5	4494_UP
Drug	Griseofulvin [126-07-8]; Up 200; 11.2uM; MCF7; HT_HG-U133A	OAS1 RUNDC3A PHF8 ZC3H13 FRMPD1	1.68e-05	199	37	5	4687_UP
Drug	Androsterone [53-41-8]; Down 200; 13.8uM; PC3; HT_HG-U133A	APC OAS1 FYN AASS FRMPD1	1.68e-05	199	37	5	4635_DN
Drug	Methotrimeprazine maleat salt [7104-38-3]; Down 200; 9uM; PC3; HT_HG-U133A	OAS1 MRAS USP9Y CDON LARGE1	1.68e-05	199	37	5	3701_DN
Drug	Rescinnamin [24815-24-5]; Up 200; 6.4uM; HL60; HT_HG-U133A	RUNDC3A VPS13B ZC3H13 CDON	2.31e-04	186	37	4	2130_UP
Drug	17-AAG; Up 200; 1uM; PC3; HT_HG-U133A	OAS1 RNF2 ZC3H13 CDON	2.45e-04	189	37	4	4450_UP
Drug	(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Up 200; 11.8uM; MCF7; HT_HG-U133A	OAS1 RUNDC3A FYN IMPG2	2.55e-04	191	37	4	4367_UP
Drug	Proglumide [6620-60-6]; Up 200; 12uM; MCF7; HT_HG-U133A	OAS1 MRAS VPS13B ZC3H13	2.55e-04	191	37	4	3861_UP
Drug	Betamethasone [378-44-9]; Up 200; 10.2uM; PC3; HT_HG-U133A	OAS1 RUNDC3A TFAP2B ZC3H13	2.60e-04	192	37	4	6728_UP
Drug	estradiol, USP; Up 200; 0.01uM; MCF7; HT_HG-U133A	APC RUNDC3A VPS13B CDON	2.60e-04	192	37	4	5238_UP
Drug	2-Aminobenzenesulfonamide [3306-62-5]; Down 200; 23.2uM; MCF7; HT_HG-U133A	APC RNF2 VPS13B VPS50	2.60e-04	192	37	4	3400_DN
Drug	0179445-0000 [211246-22-9]; Up 200; 10uM; PC3; HT_HG-U133A	APC OAS1 RUNDC3A ZC3H13	2.66e-04	193	37	4	4289_UP
Drug	Guanfacine hydrochloride [29110-48-3]; Down 200; 14.2uM; MCF7; HT_HG-U133A	APC SUPT6H ZC3H13 VPS50	2.66e-04	193	37	4	5256_DN
Drug	Piromidic acid [19562-30-2]; Down 200; 13.8uM; HL60; HT_HG-U133A	OAS1 MRAS RASA3 FRMPD1	2.66e-04	193	37	4	2996_DN
Drug	Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride; Down 200; 16.4uM; PC3; HT_HG-U133A	RUNDC3A RNF2 FYN FRMPD1	2.66e-04	193	37	4	4226_DN
Drug	FPL 64176	APC CACNB2	2.66e-04	15	37	2	CID000003423
Drug	Parbendazole [14255-87-9]; Up 200; 16.2uM; PC3; HT_HG-U133A	OAS1 PHF8 ZC3H13 IMPG2	2.71e-04	194	37	4	3799_UP
Drug	Cefaclor [70356-03-5]; Up 200; 10.4uM; MCF7; HT_HG-U133A	APC RIOK3 CACNB2 ZC3H13	2.71e-04	194	37	4	4967_UP
Drug	Clobetasol propionate [25122-46-7]; Up 200; 8.6uM; MCF7; HT_HG-U133A	SORBS1 TFAP2B SUPT6H VPS50	2.71e-04	194	37	4	6835_UP
Drug	Carbachol [51-83-2]; Up 200; 21.8uM; MCF7; HT_HG-U133A	APC OAS1 CACNB2 SORBS1	2.71e-04	194	37	4	5342_UP
Drug	Tadjakonine [11087-94-8]; Up 200; 7.4uM; PC3; HT_HG-U133A	APC RIOK3 RNF2 VPS50	2.71e-04	194	37	4	4599_UP
Drug	Piromidic acid [19562-30-2]; Up 200; 13.8uM; PC3; HT_HG-U133A	RIOK3 RUNDC3A TFAP2B LARGE1	2.71e-04	194	37	4	4575_UP
Drug	Terconazole [67915-31-5]; Up 200; 7.6uM; MCF7; HT_HG-U133A	USP9Y RASA3 TFAP2B VPS13B	2.71e-04	194	37	4	2844_UP
Drug	Triflusal [322-79-2]; Down 200; 16.2uM; MCF7; HT_HG-U133A	APC RNF2 SUPT6H VPS13B	2.76e-04	195	37	4	2867_DN
Drug	Fluspirilen [1841-19-6]; Up 200; 8.4uM; PC3; HT_HG-U133A	OAS1 SORBS1 ZC3H13 LARGE1	2.76e-04	195	37	4	6662_UP
Drug	diclofenac sodium; Up 200; 10uM; PC3; HG-U133A	APC OAS1 TGM3 ZC3H13	2.76e-04	195	37	4	445_UP
Drug	Spectinomycin dihydrochloride [21736-83-4]; Up 200; 9.8uM; MCF7; HT_HG-U133A	CACNB2 RUNDC3A RASA3 VPS13B	2.76e-04	195	37	4	3327_UP
Drug	6-mercaptopurine monohydrate; Down 200; 10uM; PC3; HG-U133A	TJP2 ARHGAP5 RIOK3 SUPT6H	2.76e-04	195	37	4	667_DN
Drug	Heliotrine [303-33-3]; Up 200; 12.8uM; MCF7; HT_HG-U133A	CACNB2 SORBS1 RUNDC3A IMPG2	2.76e-04	195	37	4	6035_UP
Drug	Phensuximide [86-34-0]; Up 200; 21.2uM; PC3; HT_HG-U133A	APC SORBS1 AASS FRMPD1	2.82e-04	196	37	4	5097_UP
Drug	Cromolyn disodium salt [15826-37-6]; Up 200; 7.8uM; MCF7; HT_HG-U133A	RNF2 ZC3H13 CDON VPS50	2.82e-04	196	37	4	3475_UP
Drug	Famprofazone [22881-35-2]; Up 200; 10.6uM; HL60; HT_HG-U133A	APC RUNDC3A CDON FRMPD1	2.82e-04	196	37	4	2174_UP
Drug	Clofazimine [2030-63-9]; Up 200; 8.4uM; MCF7; HT_HG-U133A	EFR3B OAS1 RUNDC3A FYN	2.82e-04	196	37	4	5277_UP
Drug	Alfuzosin hydrochloride [81403-68-1]; Up 200; 9.4uM; PC3; HT_HG-U133A	OAS1 MRAS ZNF287 IMPG2	2.82e-04	196	37	4	4644_UP
Drug	Tinidazole [19387-91-8]; Up 200; 16.2uM; MCF7; HT_HG-U133A	APC TGM3 VPS13B ZC3H13	2.82e-04	196	37	4	3896_UP
Drug	Galanthamine hydrobromide [1953-04-4]; Up 200; 10.8uM; MCF7; HT_HG-U133A	APC CLDN18 FYN AASS	2.82e-04	196	37	4	4772_UP
Drug	Tolazamide [1156-19-0]; Down 200; 12.8uM; PC3; HT_HG-U133A	APC OAS1 AASS FRMPD1	2.82e-04	196	37	4	4003_DN
Drug	Pentetic acid [67-43-6]; Up 200; 10.2uM; HL60; HT_HG-U133A	OAS1 RUNDC3A AASS VPS13B	2.82e-04	196	37	4	3049_UP
Drug	Pyrithyldione [77-04-3]; Up 200; 24uM; HL60; HT_HG-U133A	MRAS TFAP2B AASS CDON	2.82e-04	196	37	4	2740_UP
Drug	Seneciphylline [480-81-9]; Down 200; 12uM; PC3; HT_HG-U133A	APC RUNDC3A FYN FRMPD1	2.82e-04	196	37	4	4238_DN
Drug	CP-944629 [668990-94-1]; Up 200; 10uM; PC3; HT_HG-U133A	APC OAS1 RNF2 CDON	2.82e-04	196	37	4	7502_UP
Drug	3-Acetylcoumarin [3949-36-8]; Up 200; 21.2uM; PC3; HT_HG-U133A	OAS1 CACNB2 ZNF287 IMPG2	2.82e-04	196	37	4	4664_UP
Drug	Cefazolin sodium salt [27164-46-1]; Down 200; 8.4uM; PC3; HT_HG-U133A	APC SORBS1 RNF2 LARGE1	2.82e-04	196	37	4	3686_DN
Drug	Cefoxitin sodium salt [33564-30-6]; Up 200; 8.8uM; HL60; HT_HG-U133A	RUNDC3A AASS CDON FRMPD1	2.82e-04	196	37	4	2735_UP
Drug	Pipenzolate bromide [125-51-9]; Up 200; 9.2uM; MCF7; HT_HG-U133A	EFR3B SORBS1 RUNDC3A USP9Y	2.82e-04	196	37	4	6821_UP
Drug	Propylthiouracil [51-52-5]; Up 200; 23.4uM; MCF7; HT_HG-U133A	APC CACNB2 RASA3 ZNF287	2.82e-04	196	37	4	2837_UP
Drug	radicicol, diheterospora chlamydosporia; Up 200; 0.1uM; PC3; HT_HG-U133A	CLDN18 RUNDC3A FYN TFAP2B	2.82e-04	196	37	4	4443_UP
Drug	(-)-Eseroline fumarate salt [104015-29-4]; Up 200; 12uM; MCF7; HT_HG-U133A	APC CACNB2 RUNDC3A MRAS	2.82e-04	196	37	4	3530_UP
Drug	Pergolide mesylate [66104-23-2]; Up 200; 9.8uM; PC3; HT_HG-U133A	OAS1 FYN SUPT6H CDON	2.82e-04	196	37	4	7271_UP
Drug	haloperidol; Up 200; 10uM; PC3; HT_HG-U133A	OAS1 RNF2 CDON VPS50	2.82e-04	196	37	4	4468_UP
Drug	Folic acid [59-30-3]; Down 200; 9uM; MCF7; HT_HG-U133A	APC CACNB2 PHF8 VPS13B	2.87e-04	197	37	4	2783_DN
Drug	S-(+)-ibuprofen [51146-56-6]; Up 200; 19.4uM; MCF7; HT_HG-U133A	APC SORBS1 FYN IMPG2	2.87e-04	197	37	4	6471_UP
Drug	PHA-00745360 [351320-33-7]; Up 200; 10uM; PC3; HT_HG-U133A	OAS1 MRAS RASA3 CDON	2.87e-04	197	37	4	4559_UP
Drug	Acetaminophen [103-90-2]; Up 200; 26.4uM; PC3; HT_HG-U133A	OAS1 AASS CDON VPS50	2.87e-04	197	37	4	6284_UP
Drug	Deoxycorticosterone [64-85-7]; Up 200; 12.2uM; PC3; HT_HG-U133A	RUNDC3A PHF8 RAX LARGE1	2.87e-04	197	37	4	6758_UP
Drug	Reserpinic acid hydrochloride; Up 200; 9.2uM; MCF7; HT_HG-U133A	OAS1 CACNB2 ZC3H13 CDON	2.87e-04	197	37	4	4948_UP
Drug	Tolbutamide [64-77-7]; Down 200; 14.8uM; MCF7; HT_HG-U133A	APC RUNDC3A RASA3 AOX1	2.87e-04	197	37	4	3886_DN
Drug	Deltaline [6836-11-9]; Up 200; 7.8uM; MCF7; HT_HG-U133A	SORBS1 PHF8 IMPG2 FRMPD1	2.87e-04	197	37	4	3925_UP
Drug	Conessine [546-06-5]; Up 200; 11.2uM; HL60; HT_HG-U133A	MRAS VPS13B ZC3H13 EEF1A2	2.87e-04	197	37	4	2135_UP
Drug	Diloxanide furoate [3736-81-0]; Up 200; 12.2uM; HL60; HT_HG-U133A	OAS1 TFAP2B AASS LARGE1	2.87e-04	197	37	4	3062_UP
Drug	Nisoxetine hydrochloride [57754-86-6]; Up 200; 13uM; HL60; HT_HG-U133A	CACNB2 MRAS VPS13B CDON	2.87e-04	197	37	4	3117_UP
Drug	Propidium iodide [25535-16-4]; Down 200; 6uM; PC3; HT_HG-U133A	APC SORBS1 AASS ZNF287	2.87e-04	197	37	4	5803_DN
Drug	PNU-0230031 [267429-39-0]; Up 200; 10uM; MCF7; HT_HG-U133A	EFR3B OAS1 RASA3 TFAP2B	2.87e-04	197	37	4	4754_UP
Drug	Stachydrine hydrochloride; Up 200; 22.2uM; MCF7; HT_HG-U133A	EFR3B SORBS1 RASA3 CDON	2.87e-04	197	37	4	6805_UP
Drug	Althiazide [5588-16-9]; Up 200; 10.4uM; MCF7; HT_HG-U133A	OAS1 RASA3 SUPT6H CDON	2.87e-04	197	37	4	6829_UP
Drug	Gemfibrozil [25812-30-0]; Up 200; 16uM; PC3; HT_HG-U133A	PHF8 TFAP2B AASS FRMPD1	2.87e-04	197	37	4	5069_UP
Drug	Methylhydantoin-5-(L) [40856-73-3]; Up 200; 35uM; HL60; HT_HG-U133A	EFR3B RUNDC3A AASS LARGE1	2.87e-04	197	37	4	3040_UP
Drug	Equilin [474-86-2]; Up 200; 15uM; HL60; HT_HG-U133A	OAS1 RUNDC3A ZC3H13 IMPG2	2.87e-04	197	37	4	3039_UP
Drug	Arcaine sulfate [14923-17-2]; Down 200; 14.8uM; MCF7; HT_HG-U133A	RASA3 SUPT6H VPS50 AOX1	2.87e-04	197	37	4	4974_DN
Drug	Chlorphensin carbamate [886-74-8]; Up 200; 16.2uM; MCF7; HT_HG-U133A	APC FYN VPS13B CDON	2.87e-04	197	37	4	2279_UP
Drug	Sisomicin sulfate [53179-09-2]; Up 200; 2.8uM; PC3; HT_HG-U133A	APC OAS1 MRAS VPS50	2.87e-04	197	37	4	4014_UP
Drug	Spiramycin [8025-81-8]; Down 200; 4.8uM; HL60; HT_HG-U133A	APC CACNB2 MRAS EEF1A2	2.87e-04	197	37	4	2558_DN
Drug	Erythromycin [114-07-8]; Up 200; 5.4uM; PC3; HT_HG-U133A	CLDN18 RUNDC3A RASA3 TFAP2B	2.87e-04	197	37	4	6729_UP
Drug	Metolazone [17560-51-9]; Up 200; 11uM; MCF7; HT_HG-U133A	EFR3B APC RUNDC3A SUPT6H	2.87e-04	197	37	4	1514_UP
Drug	Nitrarine dihydrochloride [20069-05-0]; Up 200; 10.6uM; MCF7; HT_HG-U133A	SORBS1 RUNDC3A RNF2 RASA3	2.87e-04	197	37	4	6043_UP
Drug	Oxyphenbutazone [129-20-4]; Down 200; 12.4uM; MCF7; HT_HG-U133A	CACNB2 RUNDC3A PHF8 AOX1	2.87e-04	197	37	4	3582_DN
Drug	2-propylpentanoic acid; Down 200; 200uM; MCF7; HT_HG-U133A	APC PHF8 SUPT6H AOX1	2.87e-04	197	37	4	6974_DN
Drug	Cephalexin monohydrate [23325-78-2]; Up 200; 11uM; MCF7; HT_HG-U133A	EFR3B OAS1 RASA3 IMPG2	2.87e-04	197	37	4	5250_UP
Drug	Norfloxacin [70458-96-7]; Up 200; 12.6uM; PC3; HT_HG-U133A	APC MRAS AASS FRMPD1	2.87e-04	197	37	4	7283_UP
Disease	syndromic X-linked intellectual disability (implicated_via_orthology)	PHF2 PHF8	4.26e-05	8	37	2	DOID:0060309 (implicated_via_orthology)
Disease	Neurodevelopmental Disorders	PHF2 PTEN EEF1A2	2.18e-04	93	37	3	C1535926
Disease	LEOPARD Syndrome	MRAS PTEN	3.48e-04	22	37	2	C0175704
Disease	tooth eruption	CACNB2 CDON	5.67e-04	28	37	2	GO_0044691
Disease	colorectal cancer (implicated_via_orthology)	APC FYN	6.51e-04	30	37	2	DOID:9256 (implicated_via_orthology)
Disease	bipolar I disorder	CACNB2 TFAP2B EEF1A2	7.37e-04	141	37	3	EFO_0009963
Disease	prostate cancer (implicated_via_orthology)	APC PTEN	7.88e-04	33	37	2	DOID:10283 (implicated_via_orthology)
Disease	Agents acting on the renin-angiotensin system use measurement	TJP2 CACNB2 MRAS TFAP2B	8.02e-04	335	37	4	EFO_0009931
Disease	Craniofacial Abnormalities	PTEN TFAP2B RAX	9.87e-04	156	37	3	C0376634
Disease	Cleft upper lip	PHF8 TFAP2B	1.10e-03	39	37	2	C0008924

Protein segments in the cluster

Peptide	Gene	Start	Entry
DAVYDPAEYDKHPER	AASS	276	Q9UDR5
PDTYRGKYREDHADS	ETNPPL	171	Q8TBG4
ESRDSAYVEPKEDYS	CACNB2	561	Q08289
AYVEPKEDYSHDHVD	CACNB2	566	Q08289
KYEDIYEDRHDGVPS	TFAP2B	21	Q92481
HYPSLADKYESALED	AOX1	541	Q06278
DYDPTIEDSYLKHTE	MRAS	41	O14807
EDHVFSSDYYSPLRD	RASA3	291	Q14644
LHYEYEPAADSTDVT	LARGE1	461	O95461
SDENKDDYTIPDEYR	MATR3	766	P43243
ANIEEDTPSYHRSYD	EFR3B	126	Q9Y2G0
SADDETDDPRRYQKY	OAS1	351	P00973
SSDEEYYDAADKLTP	FRMPD1	766	Q5SYB0
DSTEPAYSEKRYDEI	EEF1A2	156	Q05639
YDYEARTEDDLSFHK	FYN	91	P06241
YRPTDSDNDSDYKRD	CDON	866	Q4KMG0
RTEDEVQSYPSKHDY	CLDN18	246	P56856
SKIYPSRDEYEAHQE	RNF2	111	Q99496
DNEPDHYRYSDTTDS	PTEN	371	P60484
HYRYSDTTDSDPENE	PTEN	376	P60484
YPLTEEDHDDSAYRE	GALNTL6	91	Q49A17
YDYLTDEEERHSAES	RUNDC3A	211	Q59EK9
KDSDYVYPSLESDED	PHF2	871	O75151
FVRSKADEYYPEHTS	ARHGAP5	41	Q13017
KYEHDDRSTHFPEEE	IMPG2	666	Q9BZV3
EKSHYPDVYSREELA	RAX	156	Q9Y2V3
HDTDRNLSVDVYYDP	TGM3	301	Q08188
EDDKPTNYSERYSEE	APC	1136	P25054
YRKVHPYEDSDSSED	RIOK3	116	O14730
PKDTYYDFDAEAADH	SUPT6H	1296	Q7KZ85
KSAYQEYDSDSDVPE	VPS50	551	Q96JG6
YDYHSSSEKLKERPS	TJP2	426	Q9UDY2
THTIKLEDSYDYDDR	ZNF287	261	Q9HBT7
KSEDDDSDLYSPRYS	SORBS1	451	Q9BX66
VSYYTHRHSNPEEEE	USP9Y	366	O00507
ALEHEYEPYSRLKSD	VPS13B	601	Q7Z7G8
KDAEYIYPSLESDDD	PHF8	846	Q9UPP1
HRKEDTYPEESRSYG	ZC3H13	516	Q5T200
EALEHKDREDYVPYT	TMOD3	76	Q9NYL9